|Other Names||Stromelysin-1, SL-1, Matrix metalloproteinase-3, MMP-3, Transin-1, MMP3, STMY1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6211a was selected from the Center region of human MMP3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. MMP3 is an enzyme which degrades fibronectin, laminin, collagens III, IV, IX, and X, and cartilage proteoglycans. The enzyme is thought to be involved in wound repair, progression of atherosclerosis, and tumor initiation.
Sage, E.H., et al., J. Biol. Chem. 278(39):37849-37857 (2003).Matsuyama, A., et al., Circulation 108(12):1469-1473 (2003).Mercapide, J., et al., Int. J. Cancer 106(5):676-682 (2003).Bodemer, C., et al., J. Invest. Dermatol. 121(2):273-279 (2003).Kang, M.K., et al., Exp. Cell Res. 287(2):272-281 (2003).
If you have any additional inquiries please email technical services at email@example.com.